PYRIDOXALPHOSPHATE-6-AZOPHENYL-2';4'-DISULFONIC ACID;
PYRIDOXALPHOSPHATE-6-AZOPHENYL-2';4'-DISULFONIC ACID; 性质
储存条件 | −20°C |
---|---|
溶解度 | H2O: >10 mg/mL |
形态 | 固体 |
颜色 | 红色到橙色 |
水溶解性 | Soluble to 100 mM in water |
稳定性 | 在水溶液中不稳定 |
PPADS tetrasodiuma (1-30 μM; 10-50 minutes) inhibits Na+/Ca2+ exchanger reverse mode (NCXREV) in a time- and concentration dependent manner.
PPADS tetrasodiuma is effective at other native and recombinant P2XRs. At human P2XRs sensitivity to PPADS tetrasodiuma depended on the subtype and was highest at the hP2X1, -2, -3, -5, and -7Rs with an IC50 of ∼1–3 and ∼30 μM for the hP2X4R.
PPADS tetrasodiuma (15-60 mg/100g body weight (BW); i.p.; every 12 hours for 8 days) inhibits glomerular mesangial cells (MC) proliferation without altering proliferation of non-MC in vivo in mesangial proliferative glomerulonephritis.
Animal Model: | Male Sprague-Dawley ratsweighing 160 to 200 g (anti-Thy1 disease mode) |
Dosage: | 15 mg/100g BW, 30 mg/100g BW, 60 mg/100g BW |
Administration: | i.p.; every 12 hours for 8 days (the first PPADS injection was administered 60 minutes after disease induction, and the loading dose always contained double the amount of PPADS compared to the following injections.) |
Result: | Specifically and dose-dependently reduced early (day 3) glomerular mesangial cell proliferation without altering proliferation of non-MC. |
安全信息
安全说明 | 22-24/25 |
---|---|
WGK Germany | 3 |
提供商 | 语言 |
---|---|
英文
|
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024/04/30 | HY-101044 | PYRIDOXALPHOSPHATE-6-AZOPHENYL-2';4'-DISULFONIC ACID; PPADS tetrasodium | 192575-19-2 | 1mg | 370元 |
2024/04/30 | HY-101044 | PYRIDOXALPHOSPHATE-6-AZOPHENYL-2';4'-DISULFONIC ACID; PPADS tetrasodium | 192575-19-2 | 5mg | 750元 |